Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1995-06-06
2000-02-15
Smith, Lynette R. F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4242341, 4242651, 4242771, A61K 3921, A61K 3902, A61K 39002, A61K 3900
Patent
active
060249641
ABSTRACT:
According to certain embodiments, the invention relates to a method of producing antibodies employing an immunoconjugate produced by conjugating at least one membrane-anchoring compound with at least one partial sequence of a viral, bacterial, or protoral protein. The immunoconjugate has the advantage that it can be stored for a very long time even without cooling. According to certain embodiments, the invention relates to an immunoconjugate for the specific induction of cytotoxic T-lymphocytes which comprises a conjugate from at least one membrane anchor compound and a protein, containing at least one killer T-cell epitope, of a virus, a bacterium, a parasite or a tumor antigen, or at least one partial sequence containing at least one killer T-cell epitope of a viral, bacterial or parasite protein or of a tumor antigen.
REFERENCES:
patent: 4140763 (1979-02-01), Bachrach et al.
patent: 4401658 (1983-08-01), Bouchaudon et al.
patent: 4439425 (1984-03-01), Tarcsay et al.
patent: 4459286 (1984-07-01), Hilleman et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4605512 (1986-08-01), Schaller et al.
patent: 4639512 (1987-01-01), Audibert et al.
patent: 4666886 (1987-05-01), Baschang et al.
patent: 4769237 (1988-09-01), Bittle et al.
patent: 5017688 (1991-05-01), Gilbert et al.
Haynes, B. F. et al., "Toward an Understanding of the Correlates of Protective Immunity to HIV Infection", Science, vol. 271, Jan. 19, 1996, pp. 324-328.
Cohen, J., "Jitters Jeopardize AIDS Vaccine Trials", Science, vol. 262, Nov. 12, 1993, pp. 980-981.
Burton, D.R., et al., "Why Do We Not Have An HIV Vaccine and How Can We Make One?", Nature Medicine Vaccine Supp., vol. 4, No. 5, May 1998, pp. 495-498.
(1)Derwent Abstract (C87-009492 secondary accession) Accession No. 87-022868/04.
Australian Patent Abstract, claims 1-3, 14, 23, 24 to AU A-58943/86
Boltz et al. (1988) J. Virol. Methods 22:173-182.
Bessler et al. (1986) Prog. Leukocyte Biol. 5:337-344.
Wiesmuller et al. (Feb. 1989) Vaccines 7:29-33.
Jung et al. (1985) Angew. Chem. Int. Ed. Engl. 24:872-873.
Jung et al. (1984) Synthetic Antigens (Ann. Sclavo) n.2 :191-208.
Jung et al. (1985a) Peptides: Structure Func., Proc. Am. Pep. Sym., ed. C. Derber et al. pp. 27-30.
Jung et al. (1985b) Peptides: Structure and Func., ed. V.J. Hruby et al. pp. 179-182.
Bessler et al. (1985) Immunobiol. 170:239-244.
Wiesmuller et al. (1983) Hoppe-Seyler's Z. Physiol. Chem. Bd. 364,S. 593-606.
Prass et al. (1987) Biochem. Biophys. Acta 900:116-128.
Hummel et al. (1989) Peptides: Proc. Eur. Pept. Symp., 20th Meeting 1988, Ed. G. Jung et al., pp. 686-688.
Krug et al. (1989) Biopolymers 28:499-512.
Reitermann et al. (1989) Biol. Chem. Hoppe-Seyler 370:343-352.
Bodmer et al., "Enhanced Recognition of a Modified Peptide Antigen by Cytotoxic T Cells Specific for Influenza Nucleoprotein," Cell 52:253-258 (1988).
Rothbard et al, "A Sequence Pattern Common to T Cell Epitopes," The EMBO Journal, 7:93-100 (1988).
Deres et al., "In Vivo Priming of Virus-Specific Cytotoxic T Lymphocytes With Synthetic Lipopeptide Vaccine," Nature 342:561-564 (1989).
European Search Report issued in EP 90 12 1189 which is the foreign counterpart of the parent U.S. appln. S.N. 07/966,603.
Wunsch, Angew. Chem. (1971), pp. 773-782.
Rudinger Peptide Hormones, Parsons (ed.), U Park Press, Baltimore, pp. 1-7 (1976).
Chemical Abstracts (108:34506h) 1988.
Surovoy et al., Peptides Proceedings of the Tenth American Peptide Symposium, pp. 553-554 (May 23-28, 1987).
DiMarchi et al., Peptides Proceedings of the Tenth American Peptide Symposium, pp. 531-533 (May 23-28, 1987).
Werner et al., 42 Experientia, pp. 521-531 (1986).
Sela et al., Symposium on Synthetic Peptides as Antigens, pp. 184-199 (London, Jun. 4-6, 1985).
Geysen et al., 82 Proc. Nat'l. Acad. Sci. USA, pp. 178-182 (1985).
European Search Report for European Patent Application EP 86 10 8324.
Boheim et al., Biophysics of Structure and Mechanism, vol. 9, pp. 181-191 (1983).
Schmitt et al., Liebigs Ann. Chem., pp. 321-364 (1985).
Jung et al., Chem. Abstr., vol. 103, No. 176708W (1985).
Schmitt et al., Liebigs Ann. Chem., pp. 345-364 (1985).
Jung et al., Liebigs Ann. Chem., 9: 1608-1622 (1983).
Bessler et al., Chemical Abstracts 101 (23): 701, ref. #211690s (1984).
Johnson et al., Immunobiology 165(1): 27-35 (1983).
Jung et al., Chemical Abstracts 103 (21): 539, ref. #176708w (1985).
Bessler et al., Chemical Abstracts 104 (3), ref. #18419u (1986).
Katoh et al., Nature 329: 654-656 (1986).
European Search Report issued in EP 90 12 1189, which is the foreign counterpart of the parent U.S. appln. S.N. 07/966,603, and English translation.
European Search Report for European Patent Appln EP 86 10 8324, and English translation.
K. Falk O., Rotzschke, S. Stevanovic, G. Jung and H-G. Rammensee: Allele-Specific Motifs Revealed By Sequencing of Self-Peptides Eluted From MHC Molecules; Nature, vol. 351, pp. 290-296 (1991).
A.R.M. Townsend, J. Rothbard, F.M. Gotch, G. Bahadur, D. Wraith and A. J. McMichael: The Epitopes of Influenza Nucleoprotein Recognized by Cytotoxic T Lymphocytes Can Be Defined With Short Synthetic Peptides; Cell, vol. 44, pp. 959-968 (1986).
I. M. Roitt, J. Brostoff, D.K. Male: Immunologie: DeBoeck Universite, 3d Edition, pp. 6.11 & 8.5 (1993) & (Not Translation).
I. M. Roitt, J. Brostoff, D.K. Male: Immunology; Mosby, 3d Edition, pp. 6.10-6.13 & 8.4-8.6 (1993).
T. P. Hopp: Immunogenicity Of A Synthetic HBsAg Peptide: Enhancement By Conjungation To A Fatty Acid Carrier; Molecular Immunology, vol. 21, No. 1, pp. 13-16 (1984).
Butini et al., 1994, "Comparative Analysis of HIV-Specific CTL Activity in Lymphoid Tissue and Peripheral Blood", Abstract J306, J. of Cell. Biochem., Suppl. 18B.
Lowell et al., 1988, "Proteosome-Lipopeptide Vaccines: Enhancement of Immunogenicity for Malgica CS Peptides", Science 2401 800-802.
Bessler, et al, "Specific Anhbodies Elicited by . . . " Immunobiology 170:239-244, 1985.
Jung, et al, "Increased Production of . . . " Angew. Chem. Int. Ed. Engl. 24:872-873, 1985.
Lex, et al, 1986, "A Synthetic Analogue of Escherichia coli Lipoprotein Tripalmitoyl Pentapeptide Constitutes a Potent Immune Adjuvant." J. Immunol. 137(8):2676-2681.
Jung, et al, 1985, "Enhancement of Immune Response Using B-Lymphocyte Mitogen S Covalently Linked to Antigens." Pept. Structure Funct. Proc. Am. Pep. Symp. Ed. Derber, et al, pp. 27-30.
Gendler, et al, 1988, "A Highly Immunogenic Region of a Human Polymorphic Epithelial Mucin Expressed by Carcinomas is made up of Tandem Repeats.", J. Biol. Chem. 263 (26): 12820-12823.
Becker Gerhard
Bessler Wolfgang
Buhring Hans-Jorg
Jung Gunther
Metzger Jorg
Hoechst Aktiengesellschaft
Nelson Brett
Smith Lynette R. F.
LandOfFree
Membrane anchor/active compound conjugate, its preparation and i does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Membrane anchor/active compound conjugate, its preparation and i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Membrane anchor/active compound conjugate, its preparation and i will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1903675